H 40502
Latest Information Update: 24 Jun 2002
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antiulcers
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastro-oesophageal reflux; Peptic ulcer
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 09 Jul 1998 Phase-I clinical trials for Gastro-oesophageal reflux in Sweden (Unknown route)
- 09 Jul 1998 Phase-I clinical trials for Peptic ulcer in Sweden (Unknown route)